These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21426146)

  • 1. Respiratory syncytial virus: a prioritized or neglected target?
    Roymans D; Koul A
    Future Med Chem; 2010 Oct; 2(10):1523-7. PubMed ID: 21426146
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.
    Bonfanti JF; Roymans D
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):479-87. PubMed ID: 19562644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Respiratory syncytial virus infection in adults].
    Murris-Espin M; Didier A; Carré P; Léophonte P
    Rev Mal Respir; 1995; 12(4):397-9. PubMed ID: 7481058
    [No Abstract]   [Full Text] [Related]  

  • 4. Palivizumab.
    Gupta D; Gupta P
    Indian Pediatr; 2001 Nov; 38(11):1265-9. PubMed ID: 11721066
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 6. Compliance of pediatric centers to Italian Society of Neonatology recommendations on prevention of respiratory syncytial virus infection: results of the second season of the Previeni Study.
    Macagno F;
    Pediatr Med Chir; 2005; 27(3-4):78-87. PubMed ID: 16910455
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents.
    Felicetti T; Sarnari C; Gaito R; Tabarrini O; Manfroni G
    J Med Chem; 2024 Jul; 67(14):11543-11579. PubMed ID: 38970494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The quest for an efficacious antiviral for respiratory syncytial virus.
    Torrence PF; Powell LD
    Antivir Chem Chemother; 2002 Nov; 13(6):325-44. PubMed ID: 12718405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Infections with RS viruses in children].
    Krankenpfl J; 2004; 42(7-10):231. PubMed ID: 15675393
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses.
    Budge PJ; Graham BS
    J Antimicrob Chemother; 2004 Aug; 54(2):299-302. PubMed ID: 15254023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking Respiratory Syncytial Virus Entry: A Story with Twists.
    Weisshaar M; Cox R; Plemper RK
    DNA Cell Biol; 2015 Aug; 34(8):505-10. PubMed ID: 25961744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.
    Heylen E; Neyts J; Jochmans D
    Biochem Pharmacol; 2017 Mar; 127():1-12. PubMed ID: 27659812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of respiratory syncytial virus: antiviral therapies.
    Jafri HS
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S89-92; discussion S92-3. PubMed ID: 12671458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of respiratory syncytial virus infection.
    Welliver RC
    Curr Opin Pharmacol; 2010 Jun; 10(3):289-93. PubMed ID: 20493773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-5A-antisense chimeras: inhibitors of respiratory syncytial virus infection.
    Torrence PF
    Curr Opin Mol Ther; 1999 Jun; 1(3):307-15. PubMed ID: 11713795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico structure-based design and synthesis of novel anti-RSV compounds.
    Cancellieri M; Bassetto M; Widjaja I; van Kuppeveld F; de Haan CA; Brancale A
    Antiviral Res; 2015 Oct; 122():46-50. PubMed ID: 26259810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute respiratory infections: new viruses, less therapy options?].
    Urbanek R
    Klin Padiatr; 2008; 220(5):277-8. PubMed ID: 18716979
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense.
    Leaman DW; Longano FJ; Okicki JR; Soike KF; Torrence PF; Silverman RH; Cramer H
    Virology; 2002 Jan; 292(1):70-7. PubMed ID: 11878909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol.
    Wyde PR; Laquerre S; Chetty SN; Gilbert BE; Nitz TJ; Pevear DC
    Antiviral Res; 2005 Oct; 68(1):18-26. PubMed ID: 16112208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.